Five things worth your attention from Indian consumer and retail this morning.
1. Honda guides to 6 million, and a flat second half
Honda Motorcycle & Scooter India’s chief executive said domestic volume may land near 6 million units in FY27. It dispatched 5.75 million in FY26, so that reads as a 4.3% increase. But Honda has already shipped 3.04 million in the first half, up 13.5%, which leaves the second half slightly below the first. Industry two-wheeler sales grew 17.6% to 12.09 million over the same six months on SIAM data. The read is a deliberately conservative guide, and a company growing inside a market that is growing faster. (Autocar Professional, citing The Economic Times)
2. A 427-store electronics chain files to list
Chennai-based Sathya Agencies is preparing a Rs 600 crore IPO, split evenly between a fresh issue and an offer for sale by its promoters. It ran 427 stores as of January 31 across five southern states, about 1.90 million square feet, and calls itself India’s fifth-largest consumer electronics retailer by FY25 revenue. Fifty-four of those showrooms came from buying Unilet Appliances in Karnataka, and part of the fresh issue will pay for that deal. The timing matters: this is its first full festive quarter in Karnataka with Unilet integrated. (Business Standard)
3. ixigo’s record profit came from a stake sale
ixigo posted a net profit of Rs 63.42 crore in the September quarter against a Rs 3.46 crore loss a year earlier. Rs 36.6 crore of it was an exceptional gain from selling part of its stake in bus operator FreshBus. Operating revenue was Rs 321 crore, up 13% on the year but down 10% on the June quarter, and adjusted EBITDA of Rs 23.58 crore was the lowest in five quarters. Trains grew 16.4% and buses 23.8%; flights fell 7.5%. The softness is landing where ixigo competes hardest. (Entrackr)
4. India caps cancer drug trade margins at 30%
The National Pharmaceutical Pricing Authority has capped trade margins at 30% on 137 anti-cancer medicines, with revised retail prices from November 9. A margin cap is not a price cap: it limits what the chain between manufacturer and patient may add, so it bites hardest where that margin was widest and barely at all where it was already thin. That is why reported reductions vary so much. The regulator did the same for 42 drugs in 2019, which suggests it found the tool workable, and a workable tool tends to travel to other categories. (The Tribune)
5. Yes Madam reached Rs 79.4 crore a quarter, bootstrapped
At-home beauty platform Yes Madam reported September-quarter revenue of Rs 79.4 crore, up 69% on the year, on net transaction value of Rs 165.8 crore, up 75%. That annualises to roughly Rs 402 crore of revenue and Rs 836 crore of NTV across 55-plus cities and 10,000 service professionals. Founded in 2016, it ran almost a decade on its own cash before taking Rs 50 crore from Info Edge Growth this year. It has not disclosed profit, so the fair claim is fast growth on little outside capital, not profitable growth. (Indian Retailer)
The full edition, with the deeper reads and three quick briefs: https://theinsightlabs.in/daily/2026-10-19
If one of these is close to what you do, hit reply and tell me what you are seeing on the ground. I read everything.
— Satyam · The Insight Labs